The influence of structure on the activity and toxicity of Pt anti-cancer drugs
- 1 November 1997
- journal article
- Published by Elsevier in Coordination Chemistry Reviews
- Vol. 166, 181-223
- https://doi.org/10.1016/s0010-8545(97)00023-4
Abstract
No abstract availableThis publication has 70 references indexed in Scilit:
- Platinum(II) complexes containing iminoethers: a trans platinum antitumour agentChemico-Biological Interactions, 1995
- New Cisplatin Analogues in DevelopmentDrugs, 1993
- Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapyThe Lancet, 1991
- Comparison of the 5-Hydroxytryptamine3(Serotonin) Antagonist Ondansetron (Gr 38032F) with High-Dose Metoclopramide in the Control of Cisplatin-Induced EmesisNew England Journal of Medicine, 1990
- Efficacy of Ondansetron (Gr 38032F) and the Role of Serotonin in Cisplatin-Induced Nausea and VomitingNew England Journal of Medicine, 1990
- Tumor Inhibiting Properties of Stereoisomeric [1,2‐Bis (3‐hydroxyphenyl)ethylenediamine]dichloroplatinum(II)‐Complexes, Part II: Biological PropertiesArchiv der Pharmazie, 1989
- Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: formation, identification, and quantitationBiochemistry, 1985
- Structure and activity relationships of platinum complexes with anti-tumour activityChemico-Biological Interactions, 1975
- Studies on the antitumor activity of group VIII transition metal complexes. Part I. Platinum (II) complexesBioinorganic Chemistry, 1973
- New platinum complexes with anti-tumour activityChemico-Biological Interactions, 1972